The Specialized BioTherapeutics segment focuses on developing and commercializing treatments for rare diseases. This segment's research and development activities include Phase III clinical trials for SGX301 (cutaneous T-cell lymphoma) and SGX942 (oral mucositis in head and neck cancer). The segment also focuses on proprietary formulations of oral beclomethasone 17,21-dipropionate, including SGX203 for pediatric Crohn's disease and SGX201 for acute radiation enteritis. The segment utilizes advanced drug development methodologies and clinical trial expertise to address unmet medical needs in oncology and gastroenterology. The patient impact is significant, offering potential therapies for debilitating conditions. Market positioning is based on innovative therapies for rare diseases. Future opportunities include expanding the product pipeline and securing regulatory approvals. Clinical trials and regulatory compliance are key aspects of this segment. Partnerships and collaborations are essential for manufacturing and distribution.

The Public Health Solutions segment is dedicated to developing solutions for public health threats, including infectious diseases. This segment's research and development efforts focus on RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia and Ib clinical trials. It also includes SGX943, a melioidosis therapeutic candidate in the pre-clinical stage, and ThermoVax, a technology for thermostabilizing vaccines, and CiVax, a vaccine candidate for the prevention of COVID-19. The segment utilizes vaccine development and infectious disease treatment methodologies. The therapeutic areas covered include infectious diseases and pandemic preparedness. The patient impact is focused on preventing and treating serious infectious diseases. Market positioning is based on addressing unmet needs in public health. Future opportunities include expanding the vaccine and therapeutic pipeline and securing government contracts. Regulatory compliance and clinical trial execution are critical aspects of this segment. Partnerships and collaborations with government agencies and research institutions are essential.